Pfizer Limited

NSE PFIZER.NS

Pfizer Limited Operating Cash Flow for the year ending March 31, 2024: USD 30.79 M

Pfizer Limited Operating Cash Flow is USD 30.79 M for the year ending March 31, 2024, a -28.85% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Pfizer Limited Operating Cash Flow for the year ending March 31, 2023 was USD 43.28 M, a -50.74% change year over year.
Pfizer Limited Operating Cash Flow for the year ending March 31, 2022 was USD 87.85 M, a 50.54% change year over year.
Pfizer Limited Operating Cash Flow for the year ending March 31, 2021 was USD 58.36 M, a 36.08% change year over year.
Pfizer Limited Operating Cash Flow for the year ending March 31, 2020 was USD 42.89 M, a 204.70% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NSE: PFIZER.NS

Pfizer Limited

CEO	Ms. Meenakshi Nevatia
IPO Date	July 1, 2002
Location	India
Headquarters	The Capital
Employees	1,721
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, including neuro/central nervous system, hormones, cardiovascular, hemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, respiratory, and vitamins/minerals/nutrients. It sells its products through a network of independent distributors primarily under various brand names. The company was incorporated in 1950 and is headquartered in Mumbai, India.

Key trends

Past 5 years